Restart Life Sciences (HN30) Ratios
Restart Life Sciences Ratios
DE:HN30's free cash flow for Q2 2026 was $-506.75K. For the 2026 fiscal year, DE:HN30's free cash flow was increased by $0.00 and operating cash flow was $-506.75K. See a summary of the company’s cash flow.
| Ratios | Mar 26 | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 3.67 | 0.37 | 0.02 | 1.11 | 0.78 |
| Quick Ratio | 3.67 | 0.37 | 0.02 | 1.11 | 0.78 |
| Cash Ratio | 3.33 | 0.02 | 0.01 | 1.04 | 0.52 |
| Solvency Ratio | -2.89 | 0.46 | -1.45 | -14.71 | -6.35 |
| Operating Cash Flow Ratio | -1.49 | -0.15 | -0.33 | -5.65 | -4.61 |
| Short-Term Operating Cash Flow Coverage | -2.92 | -0.90 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 1.28M | $ -308.14K | $ -821.99K | $ 27.02K | $ -94.28K |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.14 | 0.42 | 0.00 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.19 | -0.27 | 0.00 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | 0.16 | -0.36 | 0.00 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.37 | -0.64 | -0.04 | 7.18 | 1.92 |
| Debt Service Coverage Ratio | -5.48 | -8.22 | 0.00 | -2.42 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | -1.50 | 0.00 |
| Debt to Market Cap | 0.06 | 0.09 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.01 | 0.01 | 0.00 | 0.01 | 0.00 |
| Net Debt to EBITDA | 1.01 | -0.10 | 0.01 | 0.14 | 0.08 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 152.52% | 100.00% |
| EBT Per EBIT | 103.36% | -34.13% | 99.37% | 127.18% | 91.50% |
| Return on Assets (ROA) | -78.69% | 118.04% | -3942.25% | -1267.21% | -304.67% |
| Return on Equity (ROE) | -108.04% | -75.15% | 151.05% | -9096.56% | -584.75% |
| Return on Capital Employed (ROCE) | -104.53% | 220.19% | 152.01% | -4689.63% | -639.09% |
| Return on Invested Capital (ROIC) | -87.79% | 300.42% | 152.01% | -4689.63% | -579.71% |
| Return on Tangible Assets | -78.69% | 118.04% | -3942.25% | -1267.21% | -304.67% |
| Earnings Yield | -32.82% | 24.50% | -4.17% | -2.75% | -4.39% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.01 | 0.03 | 0.01 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | -48012.83 | -11441.19 | -29074.90 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 48012.83 | 11441.19 | 29074.90 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.02 | -0.00 | -0.00 | -0.01 | -0.02 |
| Free Cash Flow Per Share | -0.02 | -0.00 | -0.00 | -0.01 | -0.02 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow Coverage Ratio | -2.92 | -0.90 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -16.93% | -7.83% | -0.95% | -1.06% | -3.18% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -3.13 | 6.00 | -23.98 | -36.31 | -22.76 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 3.29 | -3.07 | -36.21 | 3303.13 | 133.10 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -5.91 | -12.78 | -105.77 | -94.60 | -31.40 |
| Price-to-Operating Cash Flow Ratio | -5.91 | -12.78 | -105.77 | -94.60 | -31.40 |
| Price-to-Earnings Growth (PEG) Ratio | 0.01 | -0.03 | 0.44 | 1.44 | 0.24 |
| Enterprise Value Multiple | -2.15 | -1.50 | -24.41 | -74.01 | -22.72 |
| Enterprise Value | 2.88M | 985.72K | 29.35M | 136.30M | 60.89M |
| EV to EBITDA | -2.15 | -1.50 | -24.41 | -74.01 | -22.72 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -4.02 | -13.73 | -105.75 | -94.41 | -31.29 |
| EV to Operating Cash Flow | -4.02 | -13.73 | -105.74 | -94.41 | -31.29 |
| Tangible Book Value Per Share | 0.04 | -0.02 | -0.01 | 0.00 | 0.00 |
| Shareholders’ Equity Per Share | 0.04 | -0.02 | -0.01 | 0.00 | 0.00 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | -0.53 | 0.09 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -0.04 | 0.01 | -0.01 | -0.03 | -0.02 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.53 | 1.00 |
| Interest Burden | 1.03 | -0.34 | 1.02 | 1.34 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.52 | -0.32 | 0.23 | 0.59 | 0.72 |
Currency in CAD